Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial

Goebeler, M.Bata-Csörgő, ZsuzsannaDe Simone, C.Didona, B.Remenyik, ÉvaReznichenko, N.Stoevesandt, J.Ward, E. S.Parys, W.Haard, H.Dupuy, P.Verheesen, P.Schmidt, E.Joly, P.2022-03-012022-03-012022British Journal Of Dermatology. -186 : 3 (2022), p. 429-439. -Br. J. Dermatol. - 0007-0963. - 1365-21331365-21330007-0963http://hdl.handle.net/2437/328911Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trialfolyóiratcikkopen access articlehttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM100570OrvostudományokKlinikai orvostudományokhttps://onlinelibrary.wiley.com/doi/10.1111/bjd.20782http://dx.doi.org/10.1111/bjd.207822022-03-2400072855770000185120320631